Press "Enter" to skip to content

Protection rate of Pfizer / BioNTech vaccine reduced by two-thirds against South African mutation – Health News


BioNTech/Pfizer In partnership with the University of Texas in the USA, scientists have succeeded in producing the corona virus carrying the mutation emerging from South Africa in a laboratory environment.

The results of the study were published in the New England Journal of Medicine. As a result of the research, it was stated that scientists tested the virus produced against the S. Africa mutation produced in the laboratory in the blood samples of the vaccinated people.

ANTIBODY RATIO FALLS TO TWO THREE

Scientists have noted that the antibody rate has dropped to two-thirds when the virus produced against the S. Africa mutation is compared to the common type of the mutated virus in the USA. It is not known whether a two-thirds reduction in antibody level will render the vaccine ineffective against this variant, since there is no limit to what extent the antibody provides protection against the virus so far. Pei-Yong Shi, an expert at the University of Texas, who made a statement about the research, noted that the BionTech / Pfizer vaccine is also possible to protect against the variant. “I can say that the immune response created by the vaccine is far above the level required to provide protection.”

VARIANT IN SOUTH AFRICA WAS DETERMINED IN 31 COUNTRIES

The South African variant, seen as “travel-related cases” in many countries, has been detected in 31 countries so far. In some of them, it was determined that they caused clusters of cases without a travel history, especially in England, France and Israel.

CORONA MEDICINE AGAINST VIRUS HOPE


Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *